Logos Global Management LP
- SEC CIK
- 0001792126
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 38
- +6 vs. Q2 2022
- Portfolio value
- $810.9M
- +$265.8M (+48.8%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| APLSApellis Pharmaceuticals, Inc. | COM | 1,300,000 | $88.8M | 10.9% | −200,000−13.3% | Reduced | History |
| CYTKCytokinetics Inc | COM NEW | 1,700,000 | $82.4M | 10.2% | −50,000−2.9% | Reduced | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 4,135,000 | $61.7M | 7.6% | +385,000+10.3% | Added | History |
| VTYXVentyx Biosciences, Inc. | COM | 1,397,680 | $48.8M | 6.0% | −915,000−39.6% | Reduced | History |
| DSGNDesign Therapeutics, Inc. | COM | 2,797,501 | $46.8M | 5.8% | 00.0% | Unchanged | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 2,000,000 | $46.5M | 5.7% | +300,000+17.6% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 350,000 | $38.7M | 4.8% | −50,000−12.5% | Reduced | History |
| ALLKAllakos Inc. | COM | 5,936,666 | $36.3M | 4.5% | +5,936,666 | New | History |
| KRTXKaruna Therapeutics, Inc. | COM | 150,000 | $33.7M | 4.2% | 00.0% | Unchanged | History |
| ARQTArcutis Biotherapeutics, Inc. | COM | 1,525,000 | $29.1M | 3.6% | +525,000+52.5% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 2,287,321 | $29.0M | 3.6% | −612,679−21.1% | Reduced | History |
| ALXOAlx Oncology Holdings Inc | COM | 2,971,352 | $28.4M | 3.5% | −165,000−5.3% | Reduced | History |
| ISEEIVERIC bio, Inc. | COM | 1,500,000 | $26.9M | 3.3% | +1,500,000 | New | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 250,000 | $25.8M | 3.2% | +250,000 | New | History |
| DICEDICE Therapeutics, Inc. | COM | 1,085,251 | $22.0M | 2.7% | +100,000+10.1% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,000,000 | $20.5M | 2.5% | +1,000,000 | New | History |
| XENEXenon Pharmaceuticals Inc. | COM | 500,000 | $18.1M | 2.2% | +500,000 | New | History |
| IMCRImmunocore Holdings plc | ADS | 350,000 | $16.4M | 2.0% | +350,000 | New | History |
| FULCFulcrum Therapeutics, Inc. | COM | 1,950,000 | $15.8M | 1.9% | 00.0% | Unchanged | History |
| AKROAkero Therapeutics, Inc. | COM | 400,000 | $13.6M | 1.7% | +400,000 | New | History |
| NGMNGM Biopharmaceuticals Inc | COM | 850,000 | $11.1M | 1.4% | +850,000 | New | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 3,743,875 | $10.3M | 1.3% | 00.0% | Unchanged | History |
| TCDATricida, Inc. | COM | 950,000 | $9.96M | 1.2% | +950,000 | New | History |
| ALTAltimmune, Inc. | COM NEW | 750,000 | $9.58M | 1.2% | +750,000 | New | History |
| Bellus Health Inc New07987C204 | COM NEW | 800,000 | $8.45M | 1.0% | +800,000 | New | – |
| KZRKezar Life Sciences, Inc. | COM | 950,000 | $8.18M | 1.0% | 00.0% | Unchanged | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 510,000 | $5.47M | 0.7% | +510,000 | New | History |
| GERNGeron Corp | COM | 2,000,000 | $4.68M | 0.6% | +2,000,000 | New | History |
| IPSCCentury Therapeutics, Inc. | COM | 460,075 | $4.55M | 0.6% | −16,484−3.5% | Reduced | History |
| VIGLVigil Neuroscience, Inc. | COM | 205,595 | $1.87M | 0.2% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 399,801 | $1.61M | 0.2% | 00.0% | Unchanged | History |
| TILInstil Bio, Inc. | COM | 331,872 | $1.61M | 0.2% | −37,928−10.3% | Reduced | History |
| SPRBSpruce Biosciences, Inc. | COM | 1,000,000 | $1.37M | 0.2% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 127,316 | $1.12M | 0.1% | −39,210−23.5% | Reduced | History |
| LIANYLianBio | SPONSORED ADS | 307,908 | $616.0K | 0.1% | −86,578−21.9% | Reduced | History |
| TRMLTourmaline Bio, Inc. | COM | 197,913 | $521.0K | 0.1% | −73,074−27.0% | Reduced | History |
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 220,434 | $434.0K | 0.1% | 00.0% | Unchanged | History |
| Nuvation Bio Inc.67080N119 | *W EXP 07/07/202 | 66,666 | $13.0K | <0.1% | 00.0% | Unchanged | – |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| TCDATricida, Inc. | COM | $2.52M | – |
Sold out since Q2 2022 (7)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| NBIXNeurocrine Biosciences Inc | Stock | 300,000 | $29.2M | 5.4% | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 350,000 | $27.9M | 5.1% | History |
| ChemoCentryx, Inc.16383L106 | COM | 600,000 | $14.9M | 2.7% | – |
| ACADAcadia Pharmaceuticals Inc | COM | 650,000 | $9.16M | 1.7% | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 150,000 | $1.19M | 0.2% | History |
| LONALeonaBio, Inc. | COM | 220,000 | $671.0K | 0.1% | History |
| NUVLNuvalent, Inc. | COM | 33,887 | $460.0K | 0.1% | History |